Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kenya's Mother-Daughter program aims to slash cervical cancer deaths

NCT ID NCT06411938

Knowledge-focused Sponsor: Indiana University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study enrolls 2,300 Kenyan women and girls to improve cervical cancer prevention. Women provide self-collected swabs for HPV testing and undergo standard visual screening. The goal is to see if self-testing is as good as or better than current methods, and to understand what helps or hinders participation. Researchers also study anogenital warts as a possible HPV reservoir.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High Risk HPV DNA Testing (self-collected swab) and Visual Inspection with Acetic Acid (VIA)
What this could lead to
If successful, this could lead to more effective, community-based cervical cancer screening programs in Kenya, especially for HIV-infected women.
What could go wrong
This is an observational study, not a treatment trial. Results may not apply to other regions, and screening accuracy depends on many factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

9 to 55 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Kenyan Adult Women Inclusion Criteria: * ages 30 through 55 years * able/willing to sign informed consent * able to travel to Webuye clinic for VIA Exclusion Criteria: * unwilling to sign informed consent * not willing or able to travel to Webuye clinic for VIA Kenyan Girls Inclusion Criteria: * ages 9 through 14 years * willing to sign informed assent for vaccination * able to return for the second HPV vaccine dose Exclusion Criteria: * girls who are not willing or unable to return for the second HPV vaccine dose * severe allergic reaction to yeast or a previous dose of the HPV vaccine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Uterine Cervical Neoplasms cervical cancer prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer Cervical cancer prevention

Contacts and locations

Locations

  • Moi University

    Eldoret, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.